The Enterprise Operations organisation will oversee initiatives to improve processes across manufacturing, technology, procurement and shared services and assist us in our goals to consistently improve the Behring margin and increase plasma volumes at a lower cost per litre. Our purpose and our people My final priority is to enable our people to deliver this exciting new future. We will continue to invest in our leaders to build skills, enhance engagement and increase productivity. This will help embed a culture of continuous learning and personal growth to ensure that our staff feel valued, included and engaged in our mission to deliver enduring patient impact. Outlook Over the longer term, like Brian and the Board, I believe your company is in a strong position to deliver on our mission for patients in need, our partners and our shareholders. Our therapies continue to be valued by patients and healthcare systems around the world. CSL Behring will continue to focus on improving gross margins, aided by the completion during the year of the RIKA roll-out across our plasma centres. While the market conditions for CSL Seqirus remain challenging, influenza will continue to impact the public health systems. The ability of a newly separated Seqirus business to pursue its own growth strategy with a dedicated management team and a differentiated strategy ensures it will be well placed to grow market share. At CSL Vifor, the iron market continues to evolve, but we expect to maintain a leadership position and build on the momentum in our nephrology business. I look forward to updating you next year on the progress we make during the 2026 financial year. In the meantime, please take the time to review the wealth of information in this report. As ever, thank you for your support of CSL. “After many years of significant growth, it is important we stay committed to a formula that can deliver for years to come. I believe a simple and focused CSL is best for patients, our people and our shareholders and we have outlined plans to evolve our strategy to re-focus on what makes us unique.” Dr Paul McKenzie Chief Executive Officer and Managing Director CSL Limited 7 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3